1-15 of 88
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Project Oncology®Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Charles Turck, PharmD, BCPS, BCCCP
Daniel Geynisman, MD
Jonathan Henderson, MD
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Project Oncology®Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Brian P. McDonough, MD, FAAFP
Bilal Siddiqui, MD
Redefining First-Line Therapy in mCSPC: Applying Evidence in Practice
Project Oncology®Redefining First-Line Therapy in mCSPC: Applying Evidence in Practice
Brian P. McDonough, MD, FAAFP
William Oh, MD
Advancing Care for Men with Breast Cancer
On the Frontlines of Metastatic Breast CancerAdvancing Care for Men with Breast Cancer
Jose Pablo Leone, MD
Identifying Mpox Hospitalization Risks in Patients with HIV During the 2022 Outbreak
Clinician's RoundtableIdentifying Mpox Hospitalization Risks in Patients with HIV During the 2022 Outbreak
Ofole U. Mgbako, MD
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
NeuroFrontiersExploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
- advertisement
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
NeuroFrontiersCardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
NeuroFrontiersQuantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD
William Oh, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
William Oh, MD
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
On the Frontlines of Prostate CancerActive Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Lisa Newcomb, PhD
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
On the Frontlines of Prostate CancerPersonalizing Prostate Cancer Surveillance: Insights from Canary PASS
Lisa Newcomb, PhD
- advertisement
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CEExpert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Bridging the Gap: New Consensus Recommendations for Adult DMD Care
NeuroFrontiersBridging the Gap: New Consensus Recommendations for Adult DMD Care
Rosaline Quinlivan
Ryan Quigley
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
On the Frontlines of Prostate CancerRedefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Daniel J. George, MD
